BioPharma merger with BLS to create ‘global leader’ in R&D services

North American CRO BioPharma has acquired fellow contract research group Bioanalytical Laboratory Services (BLS) to “further expand and fortify its analytical services and become a global leader in clinical research.”

BioPharma, which has bases in the U.S. and Canada and a HQ in Toronto, has bought out Canadian CRO BLS for an undisclosed fee in order to get its hands on the company’s bioanalytical research center.

This hub specializes in complex method development, method validation and the analysis of biological samples for pre-clinical and early-stage clinical drug trials.

Infographic Download

Reducing Time to Clinic for Your Biomedical Applications

Gelatin methacryloyl (GelMA)-based biomaterials have been widely used in various biomedical research applications due to their suitable biological properties and tunable physical characteristics. Especially over the past 5 years, GelMA-oriented research and patent applications have been growing exponentially, and many of these research concepts are now being translated towards the clinic. Suitable GelMA biomaterials are therefore indispensable to keep pace with the newest medical innovations.

Download to learn more about the benefits of GelMA in various biomedical applications and how X-Pure® GelMA can help you in your developments.

Its assets will now be combined with BioPharma’s existing Bioanalytical Lab as the two look to become a bigger player in this research area.

Renzo DiCarlo, CEO at BioPharma Services, said: "We are very proud to combine the best of BioPharma’s existing bioanalytical lab with the best of BLS. Under the scientific leadership of [BLS’ lab director Dr. Nicola Hughes], the expanded lab at BioPharma will be able to immediately offer challenging and complex new assays while strengthening our Scientific R&D team. This is just one of a list of benefits associated with merging the assets of two great labs at BioPharma.”

Effective immediately, Dr. Hughes will be appointed to the BioPharma executive team as the VP of lab operations, according to the company’s statement.

“I am extremely excited about my team joining the BioPharma team and believe together, by offering scientific excellence, high quality assays and our commitment to providing exceptional service to our clients, we are ideally suited for the early stage research market,” Dr. Hughes said.

- check out the release

Related Articles:
Frontage doubles its bioanalytics space
Quintiles beefs up in bioanalytics ahead of Quest partnership
After Warnex buy, Biotrial jumps into bioanalytics

Suggested Articles

CTI Clinical Trial and Consulting Services is buying up fellow CRO Clinart to deepen its reach in the Middle Eastern and Northern African regions.

Viva Biotech is putting down $80 million to buy preclinical contract research organization SYNthesis and boost its outsourcing business.

Popular research network provider TriNetX has seen major interest from The Carlyle Group as it buys up a majority stake in the company.